The New-Onset Diabetes (NOD) cohort is jointly funded by NCI and NIDDK and is part of the Consortium for the study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). The CPDPC sub-contracted NOD coordination to the EDRN-DMCC. The goals of NOD are to prospectively assemble a cohort of subjects >50 and ≤85 years of age with New-Onset Diabetes (NOD), called the NOD Cohort, in order to:
Estimate the probability of pancreatic ductal adenocarcinoma (PDAC) in the NOD Cohort,
Establish a biobank of clinically annotated biospecimens including a reference set of biospecimens from pre-symptomatic PDAC and control new-onset type 2 diabetes mellitus (DM) subjects,
Facilitate validation of emerging tests for identifying NOD subjects at high risk for having PDAC using the reference set, and
Provide a platform for development of an interventional protocol for early detection of sporadic PDAC NOD subjects.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.